Cytokine driven disease and epigenetic heterogeneity in rheumatoid arthritis
Date
2025
Authors
Hughes, S.T.O.
Costa, D.
Soria, A.D.
Hill, D.
Figueras, A.C.
Scott, R.
Dimonte, S.
Monaco, F.
Jenkins, R.
Twohig, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Conference item
Citation
Rheumatology, 2025, vol.64, iss.Suppl. 3, pp.78-79
Statement of Responsibility
Stuart T O Hughes, Daniela Costa, Alicia Derrac Soria, David Hill, Ana Cardus Figueras, Reuben Scott, Sandra Dimonte, Federica Monaco, Robert Jenkins, Jason Twohig, Carol Guy, Ben Cossins, Robert Andrews, Barbara Szomolay, Ernest Choy, Ngoc-Nga Vinh, Myles Lewis, Brendan Jenkins, Stephen Turner, Tony Tiganis, Nigel Williams, Hua Yu, Constantino Pitzalis, Gareth Jones, Simon A Jones
Conference Name
British Society for Rheumatology Annual Conference (BSR) (28 Apr 2025 - 30 Apr 2025 : England, Manchester)
Abstract
Background/Aims : Therapies that target cytokine signals have revolutionised the treatment of immune-mediated inflammatory diseases. However, many patients show an inadequate response to particular drug classes, reflecting the complex and often heterogeneous nature of pathology. In rheumatoid arthritis, synovial biopsies display a broad range of cellular and molecular hallmarks of disease that classify the occurrence of myeloid-rich, fibroblast-rich, and lymphoid-rich synovitis. It is unclear whether these differences in immune pathology reflect individual disease processes or different stages in disease progression. Studies of synovial histopathology in antigen-induced arthritis (AIA) showed that Il6ra-/- mice develop a low-inflammatory pathology (lacking an immune cell infiltrate) resembling fibroblast-rich synovitis. This pathology contrasted with AIA in WT mice, which presented with a myeloid-rich inflammatory infiltrate and Il27ra-/- mice, where synovial ectopic lymphoid-like structures (ELS) resembled lymphoid-rich synovitis.
School/Discipline
Dissertation Note
Provenance
Description
Abstract citation ID: keaf142.152
Access Status
Rights
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)